50332-66-6

Usage

Uses

Used in Organic Synthesis:
3-NITRO-4-QUINOLINOL is used as a synthetic building block for the creation of various organic compounds. Its chemical structure allows it to participate in a range of reactions, making it a valuable component in the synthesis of complex molecules.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 3-NITRO-4-QUINOLINOL is used as an intermediate in the development of new drugs. Its unique chemical properties enable it to be a key component in the synthesis of various pharmaceutical compounds, potentially leading to the discovery of novel therapeutic agents.
Used in Chemical Research:
3-NITRO-4-QUINOLINOL is also utilized in chemical research as a model compound to study various reaction mechanisms and to understand the behavior of similar molecules. This helps researchers in the development of new synthetic methods and the optimization of existing ones.
Used in Material Science:
In the field of material science, 3-NITRO-4-QUINOLINOL can be used as a component in the development of new materials with specific properties. Its unique chemical structure may contribute to the creation of materials with enhanced characteristics, such as improved stability or reactivity.

InChI:InChI=1/C9H6N2O3/c12-9-6-3-1-2-4-7(6)10-5-8(9)11(13)14/h1-5H,(H,10,12)

Upstream product

• 611-36-9 quinolin-4-ol 
• 121845-92-9 2-<2-nitroethylideneamino>benzoic acid 
• 2099-63-0 anthranilic acid hydrochloride 
• 118-92-3 anthranilic acid 
• 56-57-5 4-nitroquinoline-N-oxide 
• 108-24-7 acetic anhydride 
• 529-37-3 4(1H)-quinolinone 
• 7697-37-2 nitric acid 

Downstream Products

• 132207-04-6 1H-imidazo[4,5-c]-quinolin-4-amine 
• 104001-22-1 2-phenyl-1-H-imidazo<4,5-c>quinoline 
• 132207-05-7 N-phenyl-1H-imidazo<4,5-c>quinolin-4-amine 
• 132207-07-9 (1H-Imidazo[4,5-c]quinolin-4-yl)-((R)-1-methyl-2-phenyl-ethyl)-amine 
• 132207-08-0 (1H-Imidazo[4,5-c]quinolin-4-yl)-((S)-1-methyl-2-phenyl-ethyl)-amine 
• 58401-43-7 3-amino-4-chloroquinoleine 
• 99009-85-5 N-(2-methylpropyl)-3-nitro-4-quinolinamine 
• 1382350-77-7 methyl (3-(((4-(4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl)butyl)(N,N-diethylglycyl)amino)methyl)phenyl)acetate 
• 1382350-80-2 methyl (3-(((4-(4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl)butyl)amino)methyl)phenyl)acetate 
• 1421771-49-4 C₂₀H₁₇N₃OS 
• 1421771-62-1 C₂₀H₁₉N₃O₂S₂ 
• 103862-98-2 N-(4-hydroxyquinolin-3-yl)acetamide 
• 256922-53-9 2-propyl[1,3]thiazolo[4,5-c]quinolin-4-amine 
• 99011-02-6 imiqimod 

Relevant academic research and scientific papers

IMIDAZOQUINOLINE-TYPE COMPOUNDS AND USES THEREOF

Provided in the present disclosure are imidazoquinoline-type compounds, methods for their preparation, pharmaceutical compositions thereof and their use, wherein the imidazoquinoline-type compounds, upon local administration, form depots inducing cell mediated immune response while mitigating a systemic proinflammatory immune response.

LOCALLY ACTING TOLL-LIKE RECEPTOR 7 (TLR7) AND/OR TLR8 AGONIST IMMUNOTHERAPY COMPOUNDS AND THEIR USES

Provided in the present disclosure are immunotherapy compounds, pharmaceutical compositions thereof and their use, wherein the immunotherapy compounds, upon local administration, form depots inducing cell mediated immune response while mitigating a systemic proinflammatory immune response.

Design, synthesis, and biological activity of TLR7-based compounds for chemotherapy-induced alopecia

Hair loss is a common dermatosis symptom and side-effect in cancer chemotherapeutics. Imiquimod application at mid and late telogen activated the hair follicle stem cells leading to premature hair cycle entry. Based on quinoline structure, a newly synthesized compound 6b displayed proliferation activity in vitro and in vivo through branch chain replacement and triazole ring cyclization. Toll-like receptors (TLRs) are also critical mediators of the immune system, and their activation is linked to various diseases. The present study aimed to expand new agonists within co-crystallization of TLR7 (PDB code: 5GMH); however, biological assays of NF-κB activity and NO-inhibition indicated that five selected compounds were TLR7 antagonists. Molecular docking indicated the binding mode differences: antagonists binding TLR7 in a different direction and interacting with adjacent TLR7 with difficulty in forming dimers.

SUBSTITUTED IMIDAZOQUINOLINES

The invention relates to imidazoquinoline derivatives and to pharmaceutical compositions containing the imidazoquinoline derivatives. The imidazoquinoline derivatives of the invention are useful as toll-like receptor agonists, in particular agonists of TLR7, and promote induction of certain cytokines.

SUBSTITUTED IMIDAZOQUINOLINES AS AGONISTS OF TLR7

The invention relates to imidazoquinoline derivatives and to pharmaceutical compositions containing the imidazoquinoline derivatives. The imidazoquinoline derivatives of the invention are useful as toll-like receptor agonists, in particular agonists of TLR7, and promote induction of certain cytokines.

Nitrogenous five-membered heterocycle quinoline compound and salt, preparation method, pharmaceutical composition and application thereof

The invention relates to a nitrogenous five-membered heterocycle quinoline compound and a salt, a preparation method, a pharmaceutical composition and application thereof. The structural formula of the nitrogenous five-membered heterocycle quinoline compound is shown by I in the description; the preparation method of the nitrogenous five-membered heterocycle quinoline compound comprises the following steps: with a 4-hydroxyquinoline compound as a starting raw material, sequentially performing nitrification, halogenation, amination, reduction and cyclization reaction to obtain a final product.The nitrogenous five-membered heterocycle quinoline compound and the pharmaceutically acceptable salt thereof have the advantages that a hair follicle proliferation function can be realized and can beused for preparing medicines for treating common alopecia, alopecia caused by chemoradiotherapy and hair follicle damage.

NLRP3 MODULATORS

This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that modulate (e.g., agonize or partially agonize) NLRP3 and TLR7 and/or TLR8 that are useful, e.g., for treating a condition, disease or disorder in which a decrease in NLRP3 and TLR7 and/or TLR8 activities (e.g., a condition, disease or disorder associated with repressed or impaired NLRP3 and TLR7 and/or TLR8 signaling) contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This disclosure also features compositions as well as other methods of using and making the same.

Dual inhibitors of epidermal growth factor receptor and topoisomerase IIα derived from a quinoline scaffold

Based on the quinazoline bearing EGFR inhibitors, a series of thirty four compounds having a quinoline scaffold were synthesised and evaluated in vitro for EGFR kinase inhibitory activity. A structure-activity relationship study revealed that 2,4-bis(arylamino) substituted quinolines possessed better anti-EGFR kinase activity. Compounds 3f and 3m emerged as potent EGFR kinase inhibitors (200 and 210 nM, respectively) and showed excellent anticancer activity at the micromolar level against a panel of cancer cell lines comparable to erlotinib. Furthermore, representative compounds inhibited the human topoisomerase IIα selectively and catalytically, did not intercalate with DNA, increased intracellular ROS concentration (except 3m) and altered the mitochondrial membrane potential of the cancer cells. Cell cycle analysis and annexin-V staining in a lung cancer cell line showed that the compounds delayed cell cycle progression by inducing cell cycle arrest and subsequent apoptosis at the G1 phase. The facts were further corroborated through molecular modeling studies.

The new substd. Imidazoquinoline

Imidazoquinolines of formula I that contain substituted amine or amide functionality at 1- position and that are effective as Toll like Receptor 7 activators are disclosed. These compounds are useful as anticancer agents.

CONJUGATED TLR7 AND/OR TLR8 AND TLR2 AGONISTS

A conjugated compound of formula Q-Z—R4 wherein Q is a TLR7 and/or TLR8 agonist and Z—R4 is a TLR2 agonist, and the uses thereof in the treatment of infection, cancer or immune disorders or for use in vaccines.